Document is current
Any future updates will be listed below
-
Authors
Sin, Wei-Xiang https://orcid.org/0000-0003-2958-9165
Jagannathan, N. Suhas https://orcid.org/0000-0002-1857-8789
Teo, Denise Bei Lin
Kairi, Faris
Fong, Shin Yie
Tan, Joel Heng Loong
Sandikin, Dedy
Cheung, Ka-Wai
Luah, Yen Hoon
Wu, Xiaolin https://orcid.org/0000-0001-6924-292X
Raymond, Joshua Jebaraj https://orcid.org/0009-0004-3410-0496
Lim, Francesca Lorraine Wei Inng
Lee, Yie Hou https://orcid.org/0000-0003-2723-2023
Seng, Michaela Su-Fern https://orcid.org/0000-0002-6245-2446
Soh, Shui Yen
Chen, Qingfeng https://orcid.org/0000-0001-6437-1271
Ram, Rajeev J. https://orcid.org/0000-0003-0420-2235
Tucker-Kellogg, Lisa https://orcid.org/0000-0002-1301-7069
Birnbaum, Michael E. https://orcid.org/0000-0002-2281-3518
-
Funding
Funding for this research was provided by:
National Research Foundation Singapore
Agency for Science, Technology and Research
Goh Foundation Limited
- License Information
-
More Information
Article History
Received: 7 April 2023
Accepted: 20 April 2024
First Online: 4 June 2024
Competing interests
: M.E.B. is an equity holder in 3T Biosciences, is a cofounder, equity holder and consultant of Kelonia Therapeutics and Abata Therapeutics, and receives research funding from Pfizer unrelated to this work. The other authors declare no competing interests.
